EVI1 expression in acute myeloid leukaemia

Langabeer, S. E., Rogers, J. R., Harrison, G., Wheatley, K., Walker, H., Bain, B. J., Burnett, Alan Kenneth, Goldstone, A. H., Linch, D. C. and Grimwade, D. 2001. EVI1 expression in acute myeloid leukaemia. British Journal of Haematology 112 , pp. 208-211. 10.1046/j.1365-2141.2001.02569.x

Full text not available from this repository.

Abstract

Acute myeloid leukaemia (AML) with 3q26 cytogenetic abnormalities is associated with overexpression of EVI1, dysmegakaryopoiesis and poor prognosis. Screening for EVI1 transcripts was performed in 336 cases of AML, including 139 patients with acute promyelocytic leukaemia (APL). Expression was detected in 7 out of 10 cases with and 23 out of 326 without 3q26 abnormalities including one APL case. Among cases lacking 3q abnormalities, detection of EVI1 transcripts was neither associated with characteristic dysmegakaryopoietic features, nor predictive of a poor outcome, indicating that screening will probably not assist in treatment stratification. This study nevertheless demonstrates that deregulation of EVI1, although rare in APL, is a relatively frequent event in AML.

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Medicine
Subjects:	R Medicine > R Medicine (General) R Medicine > RZ Other systems of medicine
Uncontrolled Keywords:	AML, APL, EVI1, 3q26, clinical trials
Publisher:	Wiley-Blackwell
ISSN:	0007-1048
Last Modified:	25 Jun 2017 04:46
URI:	https://orca.cardiff.ac.uk/id/eprint/60496

Citation Data

Cited 51 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item